Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis: Conveyance times of primovist in hepatobiliary system

Abdallah Ahmed Elbakkoush, Anas Khaleel, Suleman Atique, Albakush Nura Ahmed Mohamed, Isatou Sowe, Chien Tsai Liu

Research output: Contribution to journalArticle

Abstract

Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalTropical Journal of Pharmaceutical Research
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Liver Cirrhosis
Magnetic Resonance Imaging
Common Hepatic Duct
Common Bile Duct
Bile Ducts
Urinary Bladder
Injections
Contrast Media
gadolinium ethoxybenzyl DTPA
Urban Hospitals
Taiwan
Duodenum

Keywords

  • Common hepatic duct
  • Gadoxetic acid
  • Hepatocellular carcinoma
  • Magnetic resonance imaging (MRI)

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis : Conveyance times of primovist in hepatobiliary system. / Elbakkoush, Abdallah Ahmed; Khaleel, Anas; Atique, Suleman; Mohamed, Albakush Nura Ahmed; Sowe, Isatou; Liu, Chien Tsai.

In: Tropical Journal of Pharmaceutical Research, Vol. 16, No. 4, 01.04.2017, p. 919-924.

Research output: Contribution to journalArticle

Elbakkoush, Abdallah Ahmed ; Khaleel, Anas ; Atique, Suleman ; Mohamed, Albakush Nura Ahmed ; Sowe, Isatou ; Liu, Chien Tsai. / Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis : Conveyance times of primovist in hepatobiliary system. In: Tropical Journal of Pharmaceutical Research. 2017 ; Vol. 16, No. 4. pp. 919-924.
@article{c96c27e7e2b847b6a99a6630f25f0edf,
title = "Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis: Conveyance times of primovist in hepatobiliary system",
abstract = "Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 {\%}) in IHD and 37 patients (78.5 {\%}) in CBD. Gall bladder reflux was visible in 26 patients (43 {\%}), and duodenal excretion in 17 patients (36 {\%}). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 {\%}) in IHD and 7 patients (15 {\%}) in CBD, while gall bladder reflux was visible in 10 patients (21 {\%}), and duodenal excretion in 20 patients (55 {\%}). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.",
keywords = "Common hepatic duct, Gadoxetic acid, Hepatocellular carcinoma, Magnetic resonance imaging (MRI)",
author = "Elbakkoush, {Abdallah Ahmed} and Anas Khaleel and Suleman Atique and Mohamed, {Albakush Nura Ahmed} and Isatou Sowe and Liu, {Chien Tsai}",
year = "2017",
month = "4",
day = "1",
doi = "10.4314/tjpr.v16i4.25",
language = "English",
volume = "16",
pages = "919--924",
journal = "Tropical Journal of Pharmaceutical Research",
issn = "1596-5996",
publisher = "Pharmacotherapy Group",
number = "4",

}

TY - JOUR

T1 - Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis

T2 - Conveyance times of primovist in hepatobiliary system

AU - Elbakkoush, Abdallah Ahmed

AU - Khaleel, Anas

AU - Atique, Suleman

AU - Mohamed, Albakush Nura Ahmed

AU - Sowe, Isatou

AU - Liu, Chien Tsai

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

AB - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

KW - Common hepatic duct

KW - Gadoxetic acid

KW - Hepatocellular carcinoma

KW - Magnetic resonance imaging (MRI)

UR - http://www.scopus.com/inward/record.url?scp=85018413664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018413664&partnerID=8YFLogxK

U2 - 10.4314/tjpr.v16i4.25

DO - 10.4314/tjpr.v16i4.25

M3 - Article

AN - SCOPUS:85018413664

VL - 16

SP - 919

EP - 924

JO - Tropical Journal of Pharmaceutical Research

JF - Tropical Journal of Pharmaceutical Research

SN - 1596-5996

IS - 4

ER -